CHRNA5 Antibody

1. Glutamatergic N398 neurons exhibited a heightened response to lower nicotine doses (0.1 μM), characterized by increased frequency and amplitude. However, they also displayed rapid desensitization, consistent with previous studies on N398-associated nicotinic receptor function. PMID: 27698409
2. Enhanced habenula-striatum functional connectivity might be modulated by the nicotinic receptor variant rs16969968, potentially leading to increased opioid use. PMID: 28857330
3. Our recent study suggested that rs667282 in CHRNA5-A3 might influence the prognosis of patients diagnosed with advanced non-small cell lung cancer. PMID: 27050379
4. Our findings confirm previous results suggesting CHRNA5 as a potential gene associated with chronic obstructive pulmonary disease (COPD) and rs8040868 as a risk variant for COPD development in the Swedish population. PMID: 27835950
5. Polymorphisms in the CHRNA5 and NRXN1 genes were linked to higher cigarette consumption among a Mexican Mestizo population. PMID: 27355804
6. The RP11-650L12.2 rs149941240 polymorphism was associated with an increased risk of colorectal cancer. PMID: 28442398
7. We identified mutations in genes not previously linked to Rett syndrome or other neurodevelopmental disorders, such as the ankyrin repeat containing protein ANKRD31 or the neuronal acetylcholine receptor subunit alpha-5 (CHRNA5), in patients with these conditions. PMID: 27541642
8. Quitting smoking significantly reduces lung cancer risks for smokers, irrespective of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes can effectively mitigate their increased genetic risk for lung cancer by quitting smoking. This action can halve their lung cancer risk and delay its onset by 7 years for those who develop it. PMID: 27543155
9. The study revealed that multiple rare, low-frequency, and common variants in the CHRNA5 gene contribute to the development of nicotine dependence. PMID: 26239294
10. Our meta-analysis did not find an association between the rs16969968 polymorphism at CHRNA5 and cancer risk in the overall pooled analysis. PMID: 27072204
11. rs2036527 is identified as a risk factor for smoking exposure and lung cancer association in African-Americans. PMID: 26981579
12. Preventive interventions implemented in adolescents reduced the genetic risk for smoking associated with rs16969968 CHRNA5. PMID: 25941207
13. Findings suggest that gene variance in the CHRNA5-CHRNA3-CHRNB4 cluster is associated with an elevated risk of death, incidence of COPD, and tobacco-related cancer among smokers. PMID: 26689306
14. These results indicate that nicotine exposure might negatively impact the apoptotic potential of chemotherapeutic drugs. Additionally, alpha5-nAChR/AKT signaling plays a crucial role in the anti-apoptotic activity of nicotine induced by cisplatin. PMID: 26909550
15. A novel regulatory SNP association with nicotine dependence was identified. Previously observed differences in CHRNA5 mRNA expression and nicotine dependence risk were linked to underlying DNA methylation differences. PMID: 26220977
16. Our meta-analysis provided statistical evidence for a strong association between rs16969968 polymorphism and the risk of lung cancer, particularly in smokers and Caucasians. PMID: 26434895
17. This study demonstrated that CHRNA5(rs16969968) interacts with chronic low family support in relation to child mental health status. PMID: 26228411
18. No associations were observed between the analyzed variants and smoking. However, an association was found among non-smoking subjects between the A allele of rs16969968 and a high body mass index. PMID: 26757861
19. In non-Hispanic White participants, a novel association between rs1289899 in the CHRNA5 gene and posttraumatic stress disorder was observed. PMID: 26184988
20. A low to moderate level of nicotine dependence among the Kashubians of Poland was demonstrated. This dependence was influenced by age, sex, and the CHRNA5 rs16969968 variant. PMID: 25652844
21. Results suggest that the minor alleles of both polymorphisms modulate response speed in a sex-dependent, diametrically opposed manner. PMID: 25674902
22. The CHRNA5 genetic risk synergized the effect of partner smoking, resulting in a particularly low likelihood of successful smoking reduction in two complementary studies. PMID: 25073833
23. Individuals with the combined variant genotypes (ins/del+del/del) of CHRNA5 rs3841324 exhibited a greater than 1.5-fold elevated risk for nasopharyngeal carcinoma. PMID: 25329654
24. Genetic variation in the CHRNA5 protein influences smoking behaviors and carbon monoxide levels. PMID: 25072098
25. CHRNA5 SNPs predicted nicotine deprivation-induced reduction in cognitive control. PMID: 24934182
26. Among smokers hospitalized with acute myocardial infarction, the high-risk CHRNA5 allele was associated with a reduced likelihood of quitting smoking before hospitalization and significantly less abstinence one year after hospitalization for MI. PMID: 24727484
27. The effect of nicotine replacement on continuous abstinence is moderated by the combined genetic risks from CYP2A6 and CHRNA5. PMID: 24033696
28. Single nucleotide polymorphism in CHRNA5 is associated with lung cancer susceptibility. PMID: 25187487
29. Data indicate that DRD2 rs1076560 and CHRNA5 rs16969968 interact to modulate cognitive function, prefrontal physiology during working memory, and prefrontal gray matter volume. PMID: 24819610
30. In African-Americans, variants (common or rare) in genes other than CHRNA5 likely contribute to the nicotine-dependent phenotype. PMID: 24682045
31. Substance dependence associated variants have a direct cis-regulatory effect on CHRNA5 transcript levels in human frontal cortices of African and European ancestry. PMID: 24303001
32. Among African Americans, CHRNA5-A3-B4 variants are not associated with smoking but can influence smoking abstinence. PMID: 24733007
33. This study investigated the association of CHRNA5 polymorphisms and smoking topography. PMID: 23358500
34. The heterozygous genotype c.-166T>A at rs503464 of CHRNA5 may be associated with a reduced risk of lung cancer, potentially representing a susceptibility allele in Chinese individuals. PMID: 23314339
35. Silencing of alpha5-nAChR significantly inhibits nicotine-induced cell proliferation in tumor cell lines. PMID: 24793809
36. Women carrying the variant AA genotype of CHRNA5 rs16969968 or variant CC genotype of LOC123688 rs8034191 had a significantly increased risk of heavy smoking. PMID: 21810735
37. The alpha5 subunit can occupy the position of a non-binding subunit or replace a beta2 subunit participating in a canonical binding site. PMID: 24184962
38. CHRNA5 polymorphism was associated with pack-year of smoking in chronic obstructive pulmonary disease Chinese Han patients. PMID: 22914670
39. This study evaluated the association between CHRNA5-A3-B4 gene cluster variants (rs667282 and rs3743073, two variants modifying lung cancer risk) and the risk of gastric cancer. PMID: 23576140
40. The rs588765 nicotine dependence risk allele 'C' was associated with delayed age at onset among ever-smokers, even when smoking intensity variables were considered. However, it had no significant effect among never-smokers. PMID: 22884254
41. Our findings provide evidence for the presence of multiple CHRNA5 mRNA isoforms that may modulate the multimeric nicotine receptor and cis-regulatory variations in the CHRNA5 locus that act in vivo in the control of CHRNA5 mRNA expression. PMID: 23430818
42. Single-nucleotide polymorphism in the CHRNA5 gene is associated with lung cancer susceptibility. PMID: 23221128
43. Findings from this study suggest that personality measures may play a significant role in substance use disorders, influencing both environmental factors (marriage) and genetic rs16969968 in CHRNA5 levels. PMID: 23308091
44. Nicotinic acetylcholine receptor single nucleotide polymorphism is associated with response to smoking cessation therapies. PMID: 23249876
45. The intronic rs871058, which is highly correlated with rs16969968 in CHRNA5, shows a modest treatment effect for subjects possessing the rare allele but has a significant effect for non-carriers. PMID: 23061658
46. Results revealed that several of the polymorphisms and their haplotypes in CHRNA5/CHRNA3 genes may have functional effects on: (i) CHRNA5 mRNA levels, (ii) polycyclic aromatic hydrocarbon-DNA adduct levels, and (iii) susceptibility to lung cancer. PMID: 23011884
47. Alpha3beta4alpha5 nicotinic acetylcholine receptors, expressing the N398 variant of CHRNA5, exhibit a reduced response to agonists when extracellular calcium is high, potentially leading to distinct downstream cellular signaling. PMID: 22820273
48. Two specific aspects of executive functioning related to drug addiction—impulsivity and working memory—are demonstrated in transgenic mice overexpressing alpha3/alpha5/beta4 nicotinic receptor subunits. PMID: 22024278
49. The A allele of the single nucleotide polymorphism rs16969968 (alpha5, G>A), which correlates with lung cancer development, shows a non-significant trend to be associated with cervical lesions. PMID: 22406075
50. Results suggest an important role for CHRNA5 variants as a genetic risk factor for airflow obstruction, potentially independent of smoking status. PMID: 22837378

Show More

Hide All

HGNC: 1959

OMIM: 118505

KEGG: hsa:1138

STRING: 9606.ENSP00000299565

UniGene: Hs.1614